Bueving Herman J, van der Wouden Johannes C
Erasmus MC-University Medical Center Rotterdam, Department of General Practice, Dr. Molewaterplein 50, 3015 GE Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
Curr Allergy Asthma Rep. 2007 Apr;7(1):72-6. doi: 10.1007/s11882-007-0033-z.
It is estimated that viruses play a role in 30% to 80% of asthma exacerbations. Thus, virus vaccination in patients with asthma could play an important role in preventing asthma exacerbations and other complications. Influenza is the only agent for which a routine vaccine is currently available. This article discusses whether influenza vaccination in patients with asthma, based on the available evidence, is justified. Cost-effectiveness of (influenza) vaccination for patients with asthma is questionable. For the other major viruses involved, the present state of affairs is described. Although progress is being made, a vaccine may be available in the near future only for respiratory syncytial virus (RSV). Meanwhile, clinicians and patients should aim for an optimal treatment with the currently available asthma medication.
Zotero 插件